Adjuvant chemotherapy for osteogenic sarcoma of the extremity with sequential adriamycin and cisplatin

✍ Scribed by Anand B. Pathak; Dr. Suresh H. Advani; Rajaram S. Iyer; Suresh K. Pai; Ramakrishna Gopal; Kanchan S. Nadkarni; Tapan K. Saikia; Purna A. Kurkure; Chandrika N. Nair; Vasant R. Pai; Rajesh Badhwar; Raman K. Deshpande; Prafulla B. Desai; Constantine P. Karakousis

• Publisher: John Wiley and Sons
• Year: 1993
• Tongue: English
• Weight: 358 KB
• Volume: 52
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930520313

✦ Synopsis

Twenty-nine patients with high-grade nonmetastatic osteogenic sarcoma of the extremities were treated with adjuvant chemotherapy following definitive surgery. Chemotherapy consisted of systemic intravenous Adriamycin and cisplatin in a sequential fashion given for six courses. Nineteen out of 29 patients are alive and continuously disease free over a follow-up period ranging from 9+ to 30+ months. The relapse-free survival was 72%, and overall survival for the entire group was 69%. Median survival is not reached yet. Six out of 29 patients relapsed, of which 1 patient is alive for 6+ months after relapse. Three patients died of chemotherapy toxicity. The results were superior to historical controls treated with surgery alone. The need for more aggressive treatment approaches is discussed.